Episurf Medical’s CEO Pål Ryfors has converted 983,607 A-shares into B-shares. The main purpose of the conversion is to enable Pål Ryfors to support Episurf Medical’s previously announced financing arrangement with European Select Growth Opportunities Fund, in which Pål Ryfors may lend B-shares to facilitate transactions under the financing arrangement. Following the conversion, Pål Ryfors owns 1,016,393 B-shares in Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.